Last updated: February 13, 2026
Overview of NDC 25021-0114
The drug identified by National Drug Code (NDC) 25021-0114 is Bupropion Hydrochloride Extended-Release (SR) and Extended-Release (XR), primarily used for depression, smoking cessation, and sometimes off-label for weight management. It is a generic medication that competes within a broad antidepressant and smoking cessation market sector.
Market Landscape
-
Market Size & Trends
- The global antidepressant market was valued at approximately USD 15 billion in 2022.
- The US represents roughly 40% of global sales.
- The market for smoking cessation drugs in the US alone exceeds USD 1 billion annually.
- Bupropion, including SR and XR formulations, accounts for roughly 25% of the antidepressant market share, valued at approximately USD 3.75 billion locally.
-
Key Competitors
- Pfizer’s Wellbutrin (brand Bupropion) remains dominant in the branded segment.
- Multiple generics have entered the market since patent expiry in 2011.
- New formulations, combo therapies, and digital health integrations influence market dynamics.
-
Regulatory & Patent Status
- Patent expiry: The original patent for Wellbutrin XR expired in 2011.
- Current status: Generic versions like NDC 25021-0114 benefit from market exclusivity shifting to competition.
- Recent regulatory actions: FDA approval of biosimilars or alternative formulations can impact pricing.
-
Market Drivers
- Increasing prevalence of depression and anxiety disorders.
- Rising awareness of smoking cessation.
- Greater physician acceptance of generics.
- Insurance coverage expanding or tightening could influence formulary placements.
-
Market Risks
- Competitive pricing pressures.
- Market saturation.
- Patient and provider preference shifts toward newer or combination therapies.
Price Trends and Projections
-
Historical Pricing Data
- Average wholesale acquisition cost (AWAC): Approximately USD 2.00–USD 3.00 per tablet for generics.
- Medicaid and private insurance reimbursements typically lower, around USD 1.50–USD 2.50 per unit.
- Retail pharmacy cash prices range USD 4.00–USD 6.00 per tablet, varying by region and pharmacy.
-
Current Pricing Dynamics
- The presence of multiple generics has driven prices downward by roughly 20% over the past five years.
- Market-mainstream discount programs (e.g., PBMs, pharmacy networks) keep prices in check.
-
Short to Medium-Term Projections
- 2023–2025: Prices are expected to stabilize with minor fluctuations within a ±10% range unless disruptive policies or new competitors enter.
- Factors influencing prices:
- Introduction of authorized generics; could lower prices further.
- Potential patent litigation or exclusivity extensions.
- Inflation or supply chain disruptions could exert upward pressures.
-
Long-Term Outlook (2026+)
- Prices likely to stabilize at current levels unless new therapies or formulations replace traditional generics.
- Market entry of targeted combination products or digital adjuncts could modify demand and pricing.
Pricing Strategies & Market Access
- Manufacturers focus on negotiated rebates and discounts with payers.
- Differentiation mainly driven through formulary placement, consumer awareness, and physician prescribing habits.
- Market penetration increases where formulary coverage is favorable and where newer branded formulations lack significant differentiation.
Summary
- The drug NDC 25021-0114 operates within a mature, competitive segment.
- Price erosion has largely plateaued, with small downward or stabilizing trends expected.
- The market’s overall valuation remains robust due to high prevalence and widespread insurance coverage.
- Market expansion depends on healthcare policy shifts, new treatment protocols, and generational health trends.
Key Takeaways
- Generics like NDC 25021-0114 face pricing pressures but maintain a substantial volume.
- The market trend indicates stability with slight declines over the next two years.
- Price management strategies will remain critical for manufacturers.
- Long-term growth hinges on new indications, formulations, or digital health advances.
FAQs
-
What factors most influence the pricing of generic bupropion?
Competition from multiple generic manufacturers, patent status of branded versions, reimbursement policies, and market demand.
-
How might new formulations affect the market?
New formulations that improve compliance or efficacy can alter market share and pricing, potentially commanding higher prices than traditional generics.
-
Are biosimilars affecting the bupropion market?
No, biosimilars are relevant for biologics, not small molecules like bupropion. However, biosimilar policies influence the broader generics market landscape.
-
Could legislation impact future prices?
Yes, policies targeting drug pricing transparency, patent reforms, or importation laws could influence prices.
-
What is the typical reimbursement rate for NDC 25021-0114?
Reimbursements range from USD 1.50 to USD 2.50 per tablet under insurance schemes, but cash prices may be higher.
Sources
[1] IQVIA. "Pharmaceutical Market Reports," 2022.
[2] FDA. "Drug Approval and Patent Data," 2022.
[3] MarketWatch. "Antidepressant Market Analysis," 2023.
[4] GoodRx. "Average Prices for Bupropion," 2023.
[5] Centers for Medicare & Medicaid Services. "Reimbursement Data," 2022.
